baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

BioCryst Pharmaceuticals Inc/ US09058V1035 /

2024-04-26 10:00:00 PM	Chg. 0.0000	Volume	Bid11:59:00 PM	Ask11:59:00 PM	High	Low
4.1600USD	0.00%	2.31 mill. Turnover: 8.14 mill.	4.1600Bid Size: 200	4.2400Ask Size: 100	4.2600	4.1100

GlobeNewswire 04-22 BioCryst to Report First Quarter 2024 Financial Results on May 6

GlobeNewswire 04-17 BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency

GlobeNewswire 04-03 BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 03-25 BioCryst to Present at Upcoming Investor Conferences

GlobeNewswire 03-12 Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corp...

GlobeNewswire 03-05 BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 02-26 BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones

GlobeNewswire 02-23 BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reduc...

GlobeNewswire 02-21 BioCryst to Present at Upcoming Investor Conferences

GlobeNewswire 02-19 BioCryst Launches ORLADEYO® (berotralstat) in Italy

GlobeNewswire 02-12 BioCryst to Report Fourth Quarter 2023 Financial Results on February 26

GlobeNewswire 02-05 BioCryst to Present New ORLADEYO® (berotralstat) Real-world Data at 2024 American Academy of Allergy...

GlobeNewswire 02-02 BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 01-05 BioCryst Announces Preliminary Full Year 2023 ORLADEYO® (berotralstat) Net Revenue of $325 Million, ...

GlobeNewswire 01-03 BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 01-03 BioCryst to Present at 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire 2023-12-19 BioCryst Announces Publication of Data from Open-label Extension of the APeX-2 Pivotal Trial of ORLA...

GlobeNewswire 2023-12-05 BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 2023-11-29 BioCryst Announces Approval of ORLADEYO® (berotralstat) by the National Administration of Drugs, Foo...

GlobeNewswire 2023-11-21 BioCryst to Present at Upcoming Investor Conferences

GlobeNewswire 2023-11-21 BioCryst Launches ORLADEYO® (berotralstat) in Spain

GlobeNewswire 2023-11-13 Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire 2023-11-10 BioCryst Presents New Real-world Data Showing Reduced Attack Rates in Patients with HAE with Normal ...

GlobeNewswire 2023-11-06 BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 2023-11-03 BioCryst R&D Day Highlights New Diversified Pipeline of First-in-Class/Best-in-Class Therapies with ...

BioCryst Pharmaceuticals Inc/ US09058V1035 /

If you wish to receive reply to your feedback, please provide your email address.